Results 91 to 100 of about 23,498 (195)

Anti-drug antibodies in patients with multiple sclerosis [PDF]

, 2013
Multiple sclerosis (MS) is an inflammatory disease affecting the brain and spinal cord and it is the main cause of neurological disability among young adults.
Ryner, Malin
core   +1 more source

Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients [PDF]

, 2012
The anti-α4 monoclonal antibody natalizumab inhibits lymphocyte extravasation into the central nervous system and increases peripheral T and B lymphocytes in multiple sclerosis patients.
Alessandra Sottini, Bielekova, Cinzia Zanotti, Crowley, del Pilar Martin, Emirena Garrafa, Fabio Torri, Federico Serana, Fletcher, Gorelik, Hug, Ifergan, Kivisäkk, Kogan, Krumbholz, Laplaud, Lee, Luigi Caimi, Luisa Imberti, Lutterotti, Marco Chiarini, Muraro, Niino, Pittet, Planas, Polman, Putzki, Ruggero Capra, Ryan, Sarah Rasia, Sawada, Schwab, Serana, Skarica, Sottini, Sottini, Stüve, Takada, van Zelm, Wipfler, Ye, Zanotti, Zohren   +42 more
core   +1 more source

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course [PDF]

, 2018
In clinical practice natalizumab is typically used in patients who have experienced breakthrough disease during treatment with interferon beta (IFNβ) or glatiramer acetate.
Hotermans, Christophe, Kappos, Ludwig, O'Connor, Paul, Pace, Amy, Polman, Christopher, Vermersch, Patrick, Wiendl, Heinz, Zhang, Annie   +7 more
core  

Autologous hematopoietic cell transplantation in multiple sclerosis. [PDF]

, 2016
INTRODUCTION: Autologous haematopoietic cell transplantation (AHCT) is an evolving treatment avenue in multiple sclerosis (MS), which may be highly effective in controlling disease activity and improving disability.
Basil Sharrack, Burt RK, John A. Snowden, La Mantia L, Martinelli Boneschi F, Simon M. Bell, van Gelder M   +6 more
core   +1 more source

Natalizumab for the treatment of relapsing multiple sclerosis

Biologics: Targets & Therapy, 2008
Richard A Rudick1, Michael A Panzara21Cleveland Clinic Foundation, Cleveland, OH, USA; 2Biogen Idec, Inc., Cambridge, MA, USAAbstract: Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple ...
Richard A Rudick, Michael A Panzara
doaj  

A Representative Survey of M.S. Patients on Attitudes toward the Benefits and Risks of Drug Therapy [PDF]

Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits.
Calfee, John E.
core   +1 more source

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Frontiers in Neurology, 2018
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiting inflammation in the central nervous system.
Maxi Kaufmann, Rocco Haase, Undine Proschmann, Tjalf Ziemssen, Katja Akgün   +4 more
doaj   +1 more source

Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta [PDF]

, 2014
Background: De-escalating natalizumab (NTZ) to interferon beta 1b (IFN B 1B) is a possible treatment option in multiple sclerosis (MS) patients interrupting NTZ because of increased risk of progressive multifocal leukoencephalopathy (PML).
Calabrese, Pasquale, Candrian, Ursula, Gobbi, Claudio, Guttmann, Charles RG, Pravatà, Emanuele, Riccitelli, Gianna C, Zecca, Chiara   +6 more
core   +2 more sources

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.
Stanley L Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O’Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle Smoot, Kiren Kresa-Reahl, Kateri J Spinelli   +12 more
doaj   +1 more source

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study

Neurology and Therapy
Introduction The TITAN study examined changes in productivity, ability to work, and quality of life (QoL) before and after treatment with the high-efficacy therapy natalizumab (TYSABRI®) in patients with multiple sclerosis (MS) in France.
Patrick Vermersch, Arnaud Kwiatkowski, Jérôme de Sèze, Alain Créange, Nathalie Texier, Sophie Fantoni-Quinton, Marilyn Gros, Marta Ruiz, Christine Lebrun-Frenay, on behalf of the TITAN Investigators   +9 more
doaj   +1 more source